OSTX.US OS Therapies Incorporated

Healthcare Biotechnology USA Stocks
0.6807 USD
Close of Nov 17, 2026
0.5799 2.25
Market cap
USD 31.9M
P/E
-
P/B
12.74x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is OSTX.US undervalued?

Graham number

The Graham number of OS Therapies Incorporated cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

OS Therapies Incorporated fundamental analysis

No fundamental analysis for OS Therapies Incorporated yet.

OS Therapies Incorporated stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About OS Therapies Incorporated

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. The company's pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH…

Full company profile